Sod1 Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mutations in the SOD1 (Superoxide Dismutase 1) gene are the second most common cause of familial amyotrophic lateral sclerosis (ALS), accounting for approximately 15-20% of inherited ALS cases[1][2]. Over 180 pathogenic mutations have been identified, making SOD1 the most extensively studied ALS gene. The discovery that SOD1 mutations cause ALS through a toxic gain-of-function mechanism revolutionized our understanding of ALS pathogenesis[3].
The SOD1 gene is located on chromosome 21q22.11 and encodes:
| Mutation | Population | Frequency | Phenotype |
|---|---|---|---|
| A4V | North America | ~50% of US cases | Rapid progression |
| G93A | Multiple | Common in research | Aggressive |
| H46R | Japan | Majority of Japanese | Slower progression |
| D90A | Scandinavia | Majority of Nordic | Variable |
| G85R | Multiple | Rare | Moderate progression |
| L126Z | Multiple | Rare | Early onset |
Mutations affect SOD1 through:
SOD1 mutations cause disease through several interconnected mechanisms:
| Mutation | Onset | Progression | Notes |
|---|---|---|---|
| A4V | ~52 years | Rapid (1-2 years) | Most aggressive |
| G93A | ~47 years | Rapid | Common in models |
| H46R | ~45 years | Slow (5-10 years) | Japanese cluster |
| D90A | ~57 years | Variable | Scandinavian |
| L126Z | ~35 years | Variable | Early onset |
| Biomarker | Utility |
|---|---|
| NfL (Neurofilament light chain) | Disease progression |
| pNfH (Phosphorylated neurofilament heavy) | Prognosis |
| Mutant SOD1 in CSF | Specific to SOD1 cases |
| Agent | Target | Phase | Outcome |
|---|---|---|---|
| Tofersen (BIIB067) | SOD1 mRNA (ASO) | Phase 3 | Primary endpoint missed, secondary benefits |
| Arl-1656 | CuATSM | Phase 2 | Completed |
| Edaravone | Oxidative stress | Approved | Modest benefit |
Tofersen (BIIB067):
Protein homeostasis enhancement
Mitochondrial protection
Neuroinflammation modulation
Sod1 Mutations In Amyotrophic Lateral Sclerosis plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sod1 Mutations In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Rosen et al., 1993 - Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis ↩︎
Banci et al., 2007 - SOD1 and familial amyotrophic lateral sclerosis ↩︎
Strong, 2010 - Toxicity of mutant copper/zinc superoxide dismutase in ALS ↩︎
Miller et al., 2022 - Phase 1 study of tofersen in SOD1-ALS ↩︎